The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
|Videos|January 20, 2021
Refining Treatment Approaches for HER2+ Breast Cancer
A discussion on systemic treatment for HER2+ breast cancer and the impact of recent clinical trial data on decision making, including data discussed at the ESMO and SABCS 2020 Annual Meetings.
Advertisement
Advertisement
Related to this article
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Obesity may increase breast cancer risk partly by removing a natural defense.
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5